Verona Pharma plc (I9SA) - Total Assets
Based on the latest financial reports, Verona Pharma plc (I9SA) holds total assets worth €572.87 Million EUR (≈ $669.75 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Verona Pharma plc - Total Assets Trend (2016–2024)
This chart illustrates how Verona Pharma plc's total assets have evolved over time, based on quarterly financial data. Also see Verona Pharma plc market capitalisation for the company's overall valuation and market capitalisation.
Verona Pharma plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verona Pharma plc's total assets of €572.87 Million consist of 95.6% current assets and 4.4% non-current assets. Review Verona Pharma plc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 84.3% |
| Accounts Receivable | €31.50 Million | 6.6% |
| Inventory | €6.25 Million | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €545.00K | 0.1% |
Asset Composition Trend (2016–2024)
This chart illustrates how Verona Pharma plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See I9SA share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verona Pharma plc's current assets represent 95.6% of total assets in 2024, an increase from 77.0% in 2016.
- Cash Position: Cash and equivalents constituted 84.3% of total assets in 2024, down from 86.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Verona Pharma plc Competitors by Total Assets
Key competitors of Verona Pharma plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Verona Pharma plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.71 | 8.61 | 12.60 |
| Quick Ratio | 10.54 | 8.61 | 12.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €497.61 Million | €367.95 Million | €195.62 Million |
Verona Pharma plc - Advanced Valuation Insights
This section examines the relationship between Verona Pharma plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 32.46 |
| Latest Market Cap to Assets Ratio | 19.12 |
| Asset Growth Rate (YoY) | 53.9% |
| Total Assets | €474.24 Million |
| Market Capitalization | $9.07 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Verona Pharma plc's assets at a significant premium (19.12x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Verona Pharma plc's assets grew by 53.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Verona Pharma plc (2016–2024)
The table below shows the annual total assets of Verona Pharma plc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €474.24 Million ≈ $554.44 Million |
+53.91% |
| 2023-12-31 | €308.12 Million ≈ $360.23 Million |
+18.75% |
| 2022-12-31 | €259.47 Million ≈ $303.35 Million |
+39.06% |
| 2021-12-31 | €186.59 Million ≈ $218.14 Million |
-8.63% |
| 2020-12-31 | €204.21 Million ≈ $238.74 Million |
+245.06% |
| 2019-12-31 | €59.18 Million ≈ $69.19 Million |
-37.20% |
| 2018-12-31 | €94.23 Million ≈ $110.17 Million |
-22.10% |
| 2017-12-31 | €120.96 Million ≈ $141.41 Million |
+112.46% |
| 2016-12-31 | €56.93 Million ≈ $66.56 Million |
-- |
About Verona Pharma plc
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more